106 Commerce Street, Suite 105
Lake Mary, FL 32746
TEL: 407.878.7606 • FAX: 407.878.7611
For additional copies, order at GuidelineCentral.com
Copyright © 2017 All rights reserved
ASCOCRPC1743
Disclaimer
is pocket card is derived om recommendations in the American Society of Clinical Oncology
Guideline. is resource is a practice tool based on ASCO
®
practice guidelines and is not intended
to substitute for the independent professional judgment of the treating physician. Practice guidelines
do not account for individual variation among patients. is pocket card does not purport to suggest
any particular course of medical treatment. Use of the practice guidelines and this resource are
voluntary. e practice guidelines and additional information are available at www.asco.org/
hCRPC-PCO. Copyright © 2017 by American Society of Clinical Oncology. All rights reserved.
Abbreviations
CRPC, castration-resistant prostate cancer; CT, computed tomography; FACBC,
18
F-flucicovine; MRI, magnetic resonance imaging ; PET, positron emission tomography;
PSA, prostate-specific antigen; PSMA, prostate-specific membrane antigen
Source
Virgo KS et al. Second-Line Hormonal erapy for Men with Chemotherapy-Naïve Castration-
Resistant Prostate Cancer (CRPC): American Society of Clinical Oncolog y Provisional Clinical
Opinion. Journal of Clinical Oncolog y 2017 April 25. DOI: 10.1200/JCO.2017.72.8030 [epub
ahead of print].
ASCO believes that cancer clinical trials are vital to inform medical decisions and
improve cancer care and that all patients should have the opportunity to participate.
Additional information, including a data supplement, a methodolog y supplement,
slide set, and other clinical tools and resources, is available at www.asco.org/hCRPC-PCO
and www.asco.org/guidelineswiki
➤ When imaging is performed for men with CRPC, a bone scan and either CT
or MRI of the abdomen and pelvis should be offered.
➤ Radiographic imaging is not indicated for men with CRPC and a rising
PSA unless treatment selection would be altered based on radiographic
findings or if symptoms potentially attributable to prostate cancer develop
or worsen (e.g., bone pain).
➤ A PSA evaluation every four to six months should be performed for men
who develop CRPC and have no radiographic evidence of metastases (M0
CRPC) and a slow PSA doubling time or velocity. If PSA levels are rising,
consider also checking serum testosterone levels.
➤ A PSA evaluation every three months is recommended for men who develop
CRPC with a rapid PSA doubling time, velocity, or radiographic evidence of
metastases (M1 CRPC).
Imaging and PSA Evaluation
